VELCADE SUMMARY
VELCADE® (bortezomib) for Injection
VELCADE® (bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) use only. Each single dose vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP.
VELCADE® (bortezomib) for Injection is indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
The effectiveness of VELCADE is based on response rates (CLINICAL STUDIES section). There are no controlled trials demonstrating a clinical benefit, such as an improvement in survival.
|